CA2381302A1 - Drug for treating fractures - Google Patents

Drug for treating fractures Download PDF

Info

Publication number
CA2381302A1
CA2381302A1 CA002381302A CA2381302A CA2381302A1 CA 2381302 A1 CA2381302 A1 CA 2381302A1 CA 002381302 A CA002381302 A CA 002381302A CA 2381302 A CA2381302 A CA 2381302A CA 2381302 A1 CA2381302 A1 CA 2381302A1
Authority
CA
Canada
Prior art keywords
bone
drug
bisphosphonate
group
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002381302A
Other languages
English (en)
French (fr)
Inventor
David G. Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Alexandra Hospital for Children
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2381302A1 publication Critical patent/CA2381302A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002381302A 1999-08-19 2000-08-17 Drug for treating fractures Abandoned CA2381302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
AUPQ2325 1999-08-19
PCT/AU2000/000982 WO2001013922A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Publications (1)

Publication Number Publication Date
CA2381302A1 true CA2381302A1 (en) 2001-03-01

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002381302A Abandoned CA2381302A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Country Status (16)

Country Link
EP (1) EP1214079A4 (hu)
JP (1) JP2003507426A (hu)
KR (1) KR20020027562A (hu)
CN (1) CN100345548C (hu)
AU (1) AUPQ232599A0 (hu)
BR (1) BR0013416A (hu)
CA (1) CA2381302A1 (hu)
HK (1) HK1048441B (hu)
HU (1) HUP0202396A3 (hu)
IL (1) IL148166A0 (hu)
NO (1) NO20020784L (hu)
NZ (1) NZ517538A (hu)
PL (1) PL353485A1 (hu)
SK (1) SK2382002A3 (hu)
WO (1) WO2001013922A1 (hu)
ZA (1) ZA200202160B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116862A (pt) 2001-02-06 2004-01-13 Royal Alexandra Hosp Children Medicamento, métodos para tratar um paciente com osteonecrose e/ou osteocondrite dissecans, para prevenir a osteonecrose e/ou osteocondrite dissecans em um paciente em risco de cada uma das ditas doenças, uso de um medicamento, e, método para prevenir a destruição da cartilagem ou condrólise associadas com osteonecrose e/ou osteocondrite dissecans
WO2002080933A1 (en) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
US8940320B2 (en) 2005-10-27 2015-01-27 Thommen Medical Ag Dental implant and production method for said implant
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN114532937A (zh) * 2020-11-18 2022-05-27 中国人民解放军海军军医大学第一附属医院 一种小肠镜辅助装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
NO20020784D0 (no) 2002-02-18
PL353485A1 (en) 2003-11-17
HK1048441B (zh) 2008-02-22
BR0013416A (pt) 2002-04-30
HK1048441A1 (en) 2003-04-04
AUPQ232599A0 (en) 1999-09-09
JP2003507426A (ja) 2003-02-25
NO20020784L (no) 2002-02-18
HUP0202396A2 (hu) 2002-11-28
CN100345548C (zh) 2007-10-31
WO2001013922A1 (en) 2001-03-01
EP1214079A4 (en) 2004-03-24
EP1214079A1 (en) 2002-06-19
ZA200202160B (en) 2003-08-27
CN1370071A (zh) 2002-09-18
HUP0202396A3 (en) 2005-02-28
NZ517538A (en) 2003-07-25
KR20020027562A (ko) 2002-04-13
SK2382002A3 (en) 2002-09-10
IL148166A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
Yıldız et al. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model
WO2002098307A1 (en) A device for the delivery of a drug to a fractured bone
Little et al. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis: A study in immature rabbits
US20040157798A1 (en) Drug for use in bone grafting
JPH09512268A (ja) 整形外科的人工器官移植後の骨吸収を阻害するためのビスホスホネートの使用
JPH08510996A (ja) 骨の手術へのビスホスホネートの使用
CA2381302A1 (en) Drug for treating fractures
Tudor et al. Static and dynamic periosteal elevation: a pilot study in a pig model
Pampu et al. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis
NO310057B1 (no) Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering
Küçük et al. Comparison of local and systemic alendronate on distraction osteogenesis
AU5973496A (en) Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
Little et al. Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis
EP2953632A1 (en) Amorphous calcium carbonate for accelerated bone growth
Tarvainen et al. Effect of clodronate on fracture healing in denervated rats
Harding et al. A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients
AU781068B2 (en) Drug for treating fractures
CA2353528C (en) Use of ibandronate for promoting osseointegration of endoprostheses
Kurth et al. Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat
Goodship et al. Prevention of strain‐related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate
Alshahrani et al. Ranitidine impairs bone healing and implant osseointegration in rats' tibiae
Kakar et al. Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals
Saghieh et al. The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study
JP2010526064A (ja) 骨組織の成長の育成および保存のための方法および組成物
Heidari et al. Effect of risedronate on bone resorption during the consolidation phase of distraction osteogenesis: a rabbit model

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued